FRI633 Financial Benefits Of Renal Dose-adjusted Dipeptidyl Peptidase-4 Inhibitors For Patients With Type 2 Diabetes And Chronic Kidney Disease: A Multicenter Study Utilizing Common Data Model

Disclosure: H. Choe: None. Y. Ko: None. S. Moon: None. C.H. Ahn: None. K. Ha: None. H. Lee: None. J. Bae: None. H. Joo: None. H. Lee: None. J. Sohn: None. D. Kim: None. S. Kim: None. K. Kim: None. Y. Cho: None. Objective: To estimate the economic benefit of replacing non-renal dose adjusted (NRDA) d...

Descripción completa

Detalles Bibliográficos
Autores principales: Jee Choe, Hun, Ko, Yeh-Hee, Joon Moon, Sun, Ahn, Chang H, Hwa Ha, Kyoung, Lee, Hyeongsuk, Hyun Bae, Jae, Joon Joo, Hyung, Lee, Hyejin, Sohn, Jang-Wook, Kim, Dae-Jung, Gon Kim, Sin, Kim, Kwangsoo, Min Cho, Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Diabetes And Glucose Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553634/
http://dx.doi.org/10.1210/jendso/bvad114.853

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10553634/
http://dx.doi.org/10.1210/jendso/bvad114.853

Ejemplares similares